(Total Views: 777)
Posted On: 10/03/2020 1:47:30 AM
Post# of 72440
My guess is Regeneron was chosen because it is progressing through its large adaptive human clinical trial. I thought Regeneron's report last week was superficial and vague.I assume Trump's physicians received more data from Regeneron.
While Brilacidin is almost certainly safer than Regeneron's monoclonal antibody drug and it has more potential as a therapeutic with its multiple therapeutic characteristics it has not been used in humans infected with Covid19 yet.
The White House and Walter Reed physicians made the right choice. If I had been in their shoes I would have done the same. IMO Brilacidin still has the most potential to be the best drug after its human trials are finished, but you just do not use the President as the first human to receive Brilicidin. .We will have to wait and see how B performs in the trials.
The real surprise is no one seems to have recommended Remdesivir. After multiple clinical trials it seems physicians are underwhelmed by its performance. My guess is Remdesivir is on its way out. I do not expect it to be used in the US and Europe in a few months.
GLTA Farrell
While Brilacidin is almost certainly safer than Regeneron's monoclonal antibody drug and it has more potential as a therapeutic with its multiple therapeutic characteristics it has not been used in humans infected with Covid19 yet.
The White House and Walter Reed physicians made the right choice. If I had been in their shoes I would have done the same. IMO Brilacidin still has the most potential to be the best drug after its human trials are finished, but you just do not use the President as the first human to receive Brilicidin. .We will have to wait and see how B performs in the trials.
The real surprise is no one seems to have recommended Remdesivir. After multiple clinical trials it seems physicians are underwhelmed by its performance. My guess is Remdesivir is on its way out. I do not expect it to be used in the US and Europe in a few months.
GLTA Farrell
(9)
(0)Scroll down for more posts ▼
